Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis

Hepatology

Volumn 48, Issue 3, 2008, Pages 871-877

  Corpechot, Christophe ^a   Abenavoli, Ludovico ^a   Rabahi, Nabila ^a   Chrétien, Yves ^a   Andréani, Tony ^a   Johanet, Catherine ^b   Chazouillères, Olivier ^a   Poupon, Raoul ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; PROTEIN ANTIBODY; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CHEMICAL ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; FEMALE; HEPATITIS; HISTOPATHOLOGY; HUMAN; LIVER TRANSPLANTATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT IDENTIFICATION; PREDICTION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROGNOSIS; REFERENCE VALUE; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BIOLOGICAL MARKERS; CHOLAGOGUES AND CHOLERETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LIVER CIRRHOSIS, BILIARY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 51349157245     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22428     Document Type: Article

References (27)

1. Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991;324:1548-1554.
2. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994;106:1284-1290.
3. Heathcote Ej, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of Ursodeoxycholic Acid in Primary Biliary Cirrhosis. HEPATOLOGY 1994;19:1149-1156.
4. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Headicote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113:884-890.
5. Poupon RE, Lindor KD, Pares A, Chazouilleres O, Poupon R, Heathcote EJ. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003;39: 12-16.
6. Poupon RE, Bonnand AM, Chretien Y, Poupon R. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology 1999;29:1668-1671.
7. Koulentaki M, Moscandrea J, Dimoulios P, Chatzicostas C, Kouroumalis EA. Survival of anti-mitochondrial antibody-positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment. Dig Dis Sci 2004;49:1190-1195.
8. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006;130:715-720.
9. ter Borg PC, Schalm. SW, Hansen BE, van Bunten HR. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006;101:2044-2050.
10. Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005;128:297-303.
11. Bormand AM, Heathcote EJ, Lindor KD, Poupon RE. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. HEPATOLOGY 1999;29:39-43.
12. Corpechot C, Carrat F, Poupon R, Poupon RE. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002;122:652-658.
13. Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. HEPATOLOGY 1998;28: 296-301.
14. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978;379:103-112.
15. Bandin O, Courvalin JC, Poupon R, Dubel L, Homberg JC, Johanet C. Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. HEPATOLOGY 1996;23:1020-1024.
16. Lindor K, Therneau T. Survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Gastroenterology 1996;111:1782-1783.
17. Lindor KD, Poupon R, Heathcote EJ, Therneau T. Ursodeoxycholic acid for primary biliary cirrhosis. Lancet 2000;355:657-658.
18. Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: A meta-analysis of randomized controlled trials. Am J Gastroenterol 2006;101:1529-1538.
19. Shapiro JM, Smith H, Schaffner F. Serum bilirubin: A prognostic factor in primary biliary cirrhosis. Gut 1979;20:137-140.
20. Krzeski P, Zych W, Kraszewska E, Milewski B, Butruk E, Habior A. Is serum bilirubin concentration the only valid prognostic marker in primary biliary cirrhosis? HEPATOLOGY 1999;30:865-869.
21. Corpechot C, Poujol-Robert A, Wendurn D, Galotte M, Chretien Y, Poupon RE, et al. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis. Liver Int 2004;24:187-193.
22. Corpechot C, Chretien Y, Chazouilleres O, Johanet C, Poupon R. Are antinuclear antibody markers early predictors of more active primary biliary cirrhosis? HEPATOLOGY 2005;42:466A.
23. Muratori P, Muratori L, Ferrari R, Cassani F, Bianchi G, Lenzi M, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003;98:431-437.
24. Rigopoulou EI, Davies ET, Pares A, Zachou K, Liaskos C, Bogdanos DP, et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 2005;54:528-532.
25. Wesierska-Gadek J, Penner E, Battezzati PM, Selmi C, Zuin M, Hitchman E, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. HEPATOLOGY 2006;43:1135-1144.
26. Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 2005;25:298-310.
27. Kumagi T, Abdalian R, Guindi M, Heathcote EJ. Progression in PBC: New insights from follow-up liver biopsies 10 years after diagnosis. HEPATOLOGY 2007;46:550A.